Company

Allogene

Allogene Therapeutics

ALLO biotech USA

Quick answer

Allogene is a biotech company (ALLO) headquartered in SOUTH SAN FRANCISCO, CA, USA with 8 tracked pipeline programs.

Pipeline (8)

ALLO-501A

Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma

Phase 2 · gene_therapy · active

1 trials project

ALLO-605

Relapsed/Refractory Multiple Myeloma

Phase 2 · gene_therapy · terminated

1 trials project

ALLO-647

Relapsed/Refractory Large B Cell Lymphoma

Phase 2 · mab · terminated

1 trials project

cemacabtagene ansegedleucel

Large B-cell Lymphoma

Phase 2 · gene_therapy · active

1 trials project

ALLO-316

Advanced/Metastatic Clear Cell Renal Cell Carcinoma

Phase 1 · gene_therapy · active

1 trials project

ALLO-329

Systemic Lupus Erythematosus (With and Without Nephritis)

Phase 1 · gene_therapy · active

1 trials project

ALLO-501

Relapsed/Refractory Large B Cell Lymphoma

Phase 1 · gene_therapy · completed

1 trials project

ALLO-715

Relapsed/Refractory Multiple Myeloma

Phase 1 · gene_therapy · completed

Patents (8)

US 12404315

Protease-activating CD45-gate CAR

Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12365873

Methods for transducing immune cells

Expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12295362

Formulations and processes for CAR T cell drug products

Expires Mon May 08 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12221462

Methods and compositions for dosing of allogeneic chimeric antigen receptor T ce

Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12215347

Chimeric antigen receptors with enhanced signaling and activities and uses there

Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12163153

Methods of manufacturing allogeneic CAR T cells

Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12163169

Inducible chimeric cytokine receptors

Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12104188

Modified caspase-9 polypeptides and methods of use thereof

Expires Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

Data sources & disclaimer

This profile compiles public regulatory and patent records for informational use by pharmaceutical professionals. It is not medical advice, not investment advice, and not an official FDA, EMA, USPTO, SEC, or NIH record. NovaPharmaNews does not represent any manufacturer, sponsor, or regulator unless explicitly stated in a separate agreement.

Patent expiry and loss-of-exclusivity dates may be estimates when derived from grant date or bulk patent metadata. Confirm material dates against the USPTO, FDA Orange Book, or counsel before contractual or regulatory decisions.

Verify critical facts using the primary sources below. See our data sources policy (methodology) and privacy policy.

Last data refresh: May 23, 2026